Neurology Drug Discovery and Development Collaboration, Option and License Agreement Sample Contracts

Amended and Restated Neurology Drug Discovery and Development Collaboration, Option and License Agreement Between Ionis Pharmaceuticals, Inc., And Biogen MA Inc.

Neurology Drug Discovery and Development Collaboration, Option and License Agreement • November 3rd, 2021 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware

• Contract Type
  Neurology Drug Discovery and Development Collaboration, Option and License Agreement
• Filed
  November 3rd, 2021
• Company
  Ionis Pharmaceuticals Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

This AMENDED AND RESTATED NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 12th day of July, 2021 (the “Amendment Date”) by and between Ionis Pharmaceuticals, Inc. (formerly known as Isis Pharmaceuticals, Inc.), a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Ionis”), and Biogen MA Inc. (formerly known as Biogen Idec MA Inc.), a Massachusetts corporation, having its principal place of business at 225 Binney Street, Cambridge, MA 02142 (“Biogen”). Biogen and Ionis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.

NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND BIOGEN IDEC MA INC.

Neurology Drug Discovery and Development Collaboration, Option and License Agreement • February 28th, 2013 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware

• Contract Type
  Neurology Drug Discovery and Development Collaboration, Option and License Agreement
• Filed
  February 28th, 2013
• Company
  Isis Pharmaceuticals Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

This NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 10th day of December, 2012 (the “Effective Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and BIOGEN IDEC MA INC., a Massachusetts corporation, having its principal place of business at 14 Cambridge Center, Cambridge, MA 02142 (“Biogen Idec”). Biogen Idec and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement.